FDA Approvals, Study Results, Multi-Year Collaborations, Data Presentations, and Supply Agreements - Research Report on Celgene, Amgen, Biogen Idec, Vertex, and Illumina

NEW YORK, September 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and Illumina, Inc. (NASDAQ: ILMN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celgene Corporation Research Report

On September 6, 2013, Celgene Corporation (Celgene) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) of ABRAXANE for treating patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. Jean-Pierre Bizzari, M.D., Executive Vice President of Hematology and Oncology at Celgene said, "For more than 15 years, treatment with gemcitabine has been the standard of care in this disease. The addition of ABRAXANE to gemcitabine demonstrated meaningful improvements across key efficacy outcomes, including overall survival, with a well-characterized safety profile." Celgene further stated that ABRAXANE in combination with gemcitabine is the first new treatment approved for metastatic adenocarcinoma of the pancreas in nearly eight years. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/CELG]

--

Amgen, Inc. Research Report

On September 1, 2013, Amgen, Inc. (Amgen) announced that treatment with AMG 145 resulted in marked reduction of upto 59% in low-density lipoprotein cholesterol (LDL-C) in an efficacy analysis of pooled data from four 12-week Phase 2 studies that evaluated AMG 145 in patient populations with high cholesterol. According to Amgen, AMG 145 is an investigational human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C from the blood. Amgen further informed that it presented the data at the ESC Congress 2013, organized by the European Society of Cardiology, in Amsterdam. Sean E. Harper, M.D., Vice President of Research and Development at Amgen said, "The data that we have accumulated in our Phase 2 clinical program is evidence that AMG 145 has the potential to help patients reach their cholesterol goals. We are conducting a large and comprehensive Phase 3 clinical program evaluating AMG 145 in multiple patient populations and utilizing two dosing schedules, with the hopes of advancing care and improving the lives of patients with uncontrolled high LDL cholesterol." The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/AMGN]

--

Biogen Idec Inc. Research Report

On September 9, 2013, Biogen Idec Inc. (Biogen Idec) announced a partnership with Isis Pharmaceuticals, Inc. (Isis) for a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. Biogen Idec stated that the agreement combines its expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders. Biogen Idec informed that in accordance to the six-year collaboration, the Company will gain exclusive rights to the use of Isis' antisense technology, under the terms that the Company will make an upfront payment of $100 million for R&D and Isis will be eligible to receive milestone payments, license fees, and royalty payments for all treatments developed through this collaboration. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/BIIB]

--

Vertex Pharmaceuticals Incorporated Research Report

On September 3, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced that five abstracts from its cystic fibrosis (CF) research and development program will be presented at the 27^th Annual North American Cystic Fibrosis Conference (NACFC) to be held between October 17, 2013 and October 19, 2013, in Salt Lake City, Utah. Vertex  informed that the Company will also present data from a Phase 3 study of ivacaftor in non-G551D gating mutations, as well as the data of long-term safety and efficacy for KALYDECO from the PERSIST open-label rollover study. The Company further added that Fred Van Goor, Ph.D., Head of Biology for Vertex's CF program, and David Rodman, M.D., Vice President of Clinical Development for Vertex's CF program, will participate in talks related to their work to discover and develop medicines that target the underlying cause of CF. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/VRTX]

--

Illumina, Inc. Research Report

On September 4, 2013, Illumina, Inc. (Illumina) announced that it has entered into a three-year agreement with Natera, Inc. (Natera). Illumina stated that in accordance with the agreement, Illumina will supply Natera with the HiSeq 2500 sequencing system and associated consumable for performing the non-invasive prenatal test (NIPT) Panorama. "We are pleased to be selected again as Natera's next-generation sequencing system provider, to support the growth of its Panorama™ test. Illumina's goal is to enable the rapid growth of NIPT and the broader reproductive health market with technology, products, and ultimately FDA-approved in vitro diagnostic systems," said Nick Naclerio, Senior Vice President of Corporate and Venture Development at Illumina. Matthew Rabinowitz, Ph.D., CEO of Natera added "We are pleased to continue working with Illumina and its next-generation sequencing technology. This deal enables a major expansion of Natera's laboratory capacity to support the fast-growing demand for our Panorama test."  The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/ILMN]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports